Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Suzhou Forlong Biotechnology Co., Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This application is assigned to 1 distinct examiner, concentrating the company's current legal efforts. This focused approach can lead to a more efficient resolution of the pending claims by allowing for a direct and consistent dialogue with the examiner. Such a strategy is particularly useful in the biotechnology sector, where technical nuances can significantly impact the scope of patent protection.
The portfolio is active in a distinct art unit, indicating a specific technical focus for the pending matter. ESSEX, LAURA ANN, is the busiest examiner, currently overseeing the pending office action. The company's immediate success in this area depends on navigating the specific requirements and prior art interpretations of this examiner. Practitioners should analyze the examiner's history with similar biological technologies to craft the most persuasive arguments for patentability.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESSEX, LAURA ANN | 1 | 60.0% | +35.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260303 | LONG-ACTING INTERLEUKIN-15 FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ESSEX, LAURA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260303 | LONG-ACTING INTERLEUKIN-15 FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ESSEX, LAURA ANN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260303 | LONG-ACTING INTERLEUKIN-15 FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ESSEX, LAURA ANN | 1675 | §102§103§112 | Non-Final OA | — | Pending | Jan 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Forlong Biotechnology Co., Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Laura Ann Essex has the most, with 1 of Suzhou Forlong Biotechnology Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
